These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21152880)

  • 21. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone deacetylase inhibitors as anti-neoplastic agents.
    Batty N; Malouf GG; Issa JP
    Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
    Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
    Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic drugs take on cancer.
    Kaiser J
    Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in gene expression induced by chemoradiation in advanced cervical carcinoma: a microarray study of RTOG C-0128.
    Zempolich K; Fuhrman C; Milash B; Flinner R; Greven K; Ryu J; Forbes A; Kerlin K; Nichols RC; Gaffney DK
    Gynecol Oncol; 2008 May; 109(2):275-9. PubMed ID: 18299147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats.
    Davidson ME; Kerepesi LA; Soto A; Chan VT
    Arch Toxicol; 2009 Aug; 83(8):747-62. PubMed ID: 19212759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
    Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
    Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substantial changes in gene expression of Wnt, MAPK and TNFalpha pathways induced by TGF-beta1 in cervical cancer cell lines.
    Kloth JN; Fleuren GJ; Oosting J; de Menezes RX; Eilers PH; Kenter GG; Gorter A
    Carcinogenesis; 2005 Sep; 26(9):1493-502. PubMed ID: 15878915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions.
    Fukuchi M; Nii T; Ishimaru N; Minamino A; Hara D; Takasaki I; Tabuchi A; Tsuda M
    Neurosci Res; 2009 Sep; 65(1):35-43. PubMed ID: 19463867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
    Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
    Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
    Jazirehi AR
    Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells.
    Ahn WS; Bae SM; Lee KH; Kim YW; Lee JM; Namkoong SE; Lee IP; Kim CK; Seo JS; Sin JI; Kim YW
    Oncol Rep; 2004 Sep; 12(3):573-80. PubMed ID: 15289840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines.
    Lee J; Yoon YS; Chung JH
    Gynecol Oncol; 2008 May; 109(2):270-4. PubMed ID: 18377964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
    Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
    Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetics and ovarian cancer.
    Nephew KP; Balch C; Zhang S; Huang TH
    Cancer Treat Res; 2009; 149():131-46. PubMed ID: 19763434
    [No Abstract]   [Full Text] [Related]  

  • 38. Epigenetic cancer therapy makes headway.
    Mack GS
    J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192
    [No Abstract]   [Full Text] [Related]  

  • 39. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
    Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
    Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic therapy for solid tumors: from bench science to clinical trials.
    Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
    Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.